|
Palo Alto, CA, February 23, 2004 — Telik, Inc. (Nasdaq:
TELK) announced that Michael M. Wick, M.D., Ph.D., chairman and
chief executive officer, will present a corporate update at the
BIO CEO and Investor Conference on February 25, 2004 at 3:00 p.m.
Eastern time (12:00 noon Pacific time) at the Waldorf-Astoria Hotel
in New York City. In addition, Dr. Wick will participate in an Industry
Focus Session on reproductive and genito-urinary cancers on February
24 at 3:30 p.m. Eastern time (12:30 p.m. Pacific time), and in an
Industry Focus Session on drug discovery on February 25 at 3:30
p.m. Eastern time (12:30 p.m. Pacific time).
Telik, Inc. of Palo Alto, California is a biopharmaceutical company
working to discover, develop and commercialize small molecule drugs
to treat serious diseases for which there is significant demand
for new therapies. The company’s most advanced drug development
candidate is TELCYTA™. Telik’s product candidates were
discovered using its proprietary drug discovery technology, TRAP,
which enables the rapid and efficient discovery of small molecule
drug candidates. Additional information is available at www.telik.com.
###
Contact:
Carol DeGuzman
Senior Director, Corporate Communications
Telik, Inc.
Tel 650-845-7728
Email cdeguzman@telik.com
Go to: 2004
Press Releases2003
Press ReleasesEvents
|
